ALDX Aldeyra Therapeutics Inc.

4.86
-0.04  -1%
Previous Close 4.9
Open 4.95
Price To Book 1.99
Market Cap 134,030,280
Shares 27,578,247
Volume 236,165
Short Ratio
Av. Daily Volume 272,661

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 3 (Part 1) to be completed 4Q 2019.
ADX-102 - topical ocular reproxalap - RENEW
Dry eye syndrome
Phase 3 data March 25, 2019 - primary endpoint met.
Reproxalap (ADX-102)
Allergic conjunctivitis
Phase 3 data did not meet endpoints - June 25, 2019.
ADX-102 reproxalap
Noninfectious anterior uveitis
Phase 3 Part 1 section of trial completed.
Reproxalap (ADX-102)
Sjögren-Larsson Syndrome (SLS)
Phase 2 trial to be initiated 2H 2019.
ADX-1612 (ganetespib)
Post-transplant lymphoproliferative disorder
Phase 3 trial to be initiated 2H 2019 with initial data due 2020.
ADX-2191
Proliferative vitreoretinopathy (PVR)
Phase 3 trial to be initiated 4Q 2019 with initial data due 2020.
ADX-2191
Proliferative vitreoretinopathy (PVR)

Latest News

  1. Edited Transcript of ALDX earnings conference call or presentation 8-Aug-19 12:00pm GMT
  2. Aldeyra Therapeutics Inc (ALDX) Q2 2019 Earnings Call Transcript
  3. Aldeyra Therapeutics Announces Second Quarter 2019 Financial Results and Provides Corporate Update
  4. Here’s What Hedge Funds Think About Aldeyra Therapeutics Inc (ALDX)
  5. No Solace For Aldeyra As Late-Stage Study Of Lead Drug In Anterior Uveitis Fails
  6. Aldeyra shares slide 29% premarket after trial of eye disease treatment fails to meet goals
  7. Aldeyra Therapeutics Announces Results from the SOLACE Trial in Noninfectious Anterior Uveitis
  8. Aldeyra Therapeutics Schedules Webcast and Conference Call to Announce Top-Line Results from the SOLACE Trial in Noninfectious Anterior Uveitis
  9. Aldeyra Therapeutics to Participate in the Jefferies 2019 Global Healthcare Conference
  10. Edited Transcript of ALDX earnings conference call or presentation 9-May-19 12:00pm GMT
  11. Aldeyra Therapeutics Announces First Quarter 2019 Financial Results and Provides Corporate Update
  12. Aldeyra Therapeutics to Report First Quarter 2019 Financial Results and Host Conference Call on Thursday, May 9, 2019
  13. Aldeyra Therapeutics Announces Last Patient Dosed in the SOLACE Phase 3 Clinical Trial
  14. Aldeyra Therapeutics Announces Presentation of Phase 2b Dry Eye Disease Results at the 2019 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting
  15. Aldeyra Therapeutics Announces First Patient Enrolled in the RENEW Phase 3 Clinical Trial for Dry Eye Disease
  16. Aldeyra's Eye Drug Meets Main Goal in Study, Shares Surge
  17. Future Brightens for 2 Small Biotech Stocks
  18. Here's Why Aldeyra Therapeutics Stock Soared as Much as 79.1% Today
  19. Aldeyra stock jumps 50 percent after eye allergy trial success